A randomized and prospective study was designed to prove the efficacy of angiotensin II receptor blockers (ARB) in the amelioration of myocardial impairment in hypertrophic nonobstructive cardiomyopathy (HNCM).
mental and animal studies 14, 15) have indicated that angiotensin II 16, 17) excretion followed by stretch stimulation or pressure load on the cardiac myocytes was associated with the process of initiation and extension of myocardial hypertrophy. The mechanism of human sarcomere disease, ie, hypertrophic cardiomyopathy, however, is completely veiled in a black-box through which the gene expressions lead to morphological disorders such as interstitial fibrosis with disarray of hypertrophied cardiac myocytes. In human hypertension, histological amelioration by angiotensin II receptor blockers (ARB) has already been proven to be much more efficient than other antihypertensive agents. 21) This indicates the autocrine and/or paracrine effects of angiotensin II are associated with the hypertrophying process in human hypertensive myocardial hypertrophy. 18) These experimental and clinical backgrounds of the pathological mechanism of myocardial hypertrophy encourage the hypotheses that genetic mutations 1) are expressed via angiotensin II receptors, and therefore, ARBs possibly inhibit gene expression and ameliorate morphological abnormalities in human hypertrophic cardiomyopathy as well.
The temporal and spatial resolution of cardiac cine magnetic resonance (MR) imaging 7, 8, 19, 20) is adequate to provide quantitative evaluation of the left ventricular mass (LVM). Isolated administration of an ARB is a contraindication in hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. Therefore, a randomized and prospective study with ARBs in human hypertrophic nonobstructive cardiomyopathy (HNCM) was conducted in order to demonstrate the therapeutic efficacy of ARBs in the amelioration of morphology evaluated using cine MR imaging.
METHODS

Study population:
Nineteen consecutive patients suspected of having HNCM who gave written informed consent were enrolled in the current study. The brief study protocol consisted of a randomized grouping of the population into two therapeutic groups and an annual cardiac MR examination before and after a single year of therapeutic intervention. The protocol was approved by the institutional review board of the University of Tokyo Hospital. The 19 patients whose clinical history, and electrocardiographic 21, 22) and echocardiographic 21) findings strongly suggested HNCM underwent the first MR examination at the time of enrolment just before the start of administration of an ARB. No pressure gradient at the left ventricular outflow tract had been detected by echocardiography. The diagnosis of HNCM was established when the first MR examination demonstrated focally confined hypertrophy with wall thickness equal to or greater than 15 mm (Table I) . Patients with a history of uncontrolled severe hypertension and/ Vol 48 No 6 or a valvular disorder such as aortic stenosis were excluded. ARB group and non-ARB group: The 19 patients with HNCM were randomly divided into two groups, an ARB group and a non-ARB group. The randomization was performed using randomizing software that matched the two groups with respect to age, systolic blood pressure, and diastolic blood pressure before the intervention period (Table II) . The randomization protocol assigned 9 patients to the ARB group and 10 patients to the non-ARB group. All subjects in the ARB group continued to take 50 mg of losartan potassium once daily for one year until the second MR examination. In the non-ARB group, antihypertensive drugs were also administered to control blood pressure during the year, if necessary. No angiotensin converting enzyme inhibitors, alpha-blockers, or antialdosterone agents were administered in either group (Table III) . There were no statistically significant differences in age or blood pressures between the two groups. There was also no difference in the maximum wall thickness of the left ventricle between the two groups. 8) twice, just before and after a one year follow-up period. MR examinations were performed using a Magnetom Vision (Siemens, Erlangen, Germany) with a 1.5 Tesla superconducting magnet. Cine loops of left ventricular short-axis MR images were obtained using an electrocardiographically triggered gradient refocused sequence (turbo-fast low angle shots). The imaging parameters were as follows: echo time of 6.2 ms, flip angle of 30 degrees, data acquisition matrix of 140 × 256, and field of view of 350 × 350 mm. The time delay for the first data acquisition window for end-diastole was 0 ms after the trigger of R waves and the window was moved toward the end of the cardiac cycle in increments of 80 ms. The entire left ventricle was encompassed by acquiring 10 mm thick contiguous short-axis cine loops with no interslice gaps. MR measurement and display standardization: Each MR measurement was performed using standardized display parameters. The NMR intensities of the myocardium and the blood pool of the left ventricle were measured on each MR image to calculate display window parameters. Window center was defined as the mean intensity of the myocardium and the blood pool, and window width was calculated by multiplying 3 by the intensity difference between the blood pool and the myocardium. LVM in cubic cm was obtained by Simpson's algorism, ie, by summing up the entire traced areas of the interventricular septum and those of the free wall of the left ventricle on every short-axis cine MR image at end-diastole with a delay time of 0 ms after R waves. LVM was calculated using the following formula:
Each measurement was conducted blindly, in other words, the investigator had no information concerning patient allotment to either the ARB or non-ARB group. Intraobserver and interobserver variability: To evaluate intraobserver variability, LVM was measured twice by a single cardiologist, while to evaluate interobserver variability, LVM was measured once by another cardiologist. The reproducibility of the LVM measurements was tested by the absolute difference between paired values measured on the common datum-set divided by the mean of the paired values. LVM ratio: The ratio of LVM after a one year observation period over LVM before the period was calculated to express the therapeutic effect of ARB on morphological amelioration in HNCM or the natural course of HNCM in humans. In other words, this ratio is defined as the value of LVM normalized by the initial LVM.
Statistical analysis: All values are expressed as the mean ± SD. Differences between the two groups were tested using a paired or unpaired t test. A significant difference is indicated by a P value of less than 0.05. Intraobserver variability and interobserver variability were tested by determining the absolute value of the difference between the two paired values over the mean of the paired two values.
RESULTS
A statistically significant difference in blood pressure between the ARB group and non-ARB group was not observed in either systole or diastole at the end of the follow-up period. Intraobserver variability and interobserver variability were 3.4 ± 2.6% and 6.6 ± 6.7%, respectively.
Although a statistically significant decrease was not observed (P = 0.07) in the ARB group, LVM was slightly reduced during the one year treatment period (initial LVM: 203 ± 47 cm (Table IV, Figures  1, 2) .
The ratio of the final LVM over the initial LVM was 0.93 ± 0.10 in the ARB group and 1.02 ± 0.07 in the non-ARB group. The ratio, ie, normalized LVM after a single year of observation in the ARB group, was significantly (P = 0.03) smaller than that in the non-ARB group (Table IV) . The temporal profile of the normalized LVM is shown in Figure 3 .
DISCUSSION
The findings of the current prospective and randomized study demonstrate that once daily administration of the ARB losartan potassium at a dose of 50 mg for one year significantly ameliorated the natural course of morphology in patients with HNCM. The current morphological evaluation using MR imaging was conducted blindly. To the best of our knowledge, this is the first clinical evi- Clinical research on hypertension has already demonstrated that the efficacy of angiotensin converting enzyme inhibitors or ARBs in ameliorating left ventricular hypertrophy was much greater than that of other kinds of antihypertensive drugs. 17) Experimental research has indicated that autocrine and/or paracrine release of angiotensin II possibly mediates the hypertrophy of cardiac myocytes, 16) while animal studies 14, 15) have demonstrated that LVM was reduced by administration of ARB in genetic hypertension or in hypertrophic cardiomyopathy in animal models. These observations strongly support the hypothesis that ARBs inhibit gene expression and reduce LVM of HNCM similarly in humans. The current study has demonstrated that administration of an ARB not only inhibited morphologic deterioration, but also ameliorated the HNCM natural course of HNCM in humans. In conclusion, the current randomized and prospectively designed study has showed that a single year of administration of ARB was sufficient to obtain a therapeutic effect on the natural course in patients with HNCM, and that cine MR imaging was sensitive enough to demonstrate a therapeutic effect on the morphology. This is the first clinical evidence supporting the possible application of ARBs as a standard treatment for HNCM.
